News headlines about Portola Pharmaceuticals (NASDAQ:PTLA) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.7947869290202 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have impacted Accern’s rankings:

Shares of Portola Pharmaceuticals (NASDAQ:PTLA) traded down $0.53 on Friday, hitting $47.02. The stock had a trading volume of 1,669,458 shares, compared to its average volume of 646,193. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.31 and a quick ratio of 8.31. Portola Pharmaceuticals has a fifty-two week low of $18.30 and a fifty-two week high of $67.10.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.08. The business had revenue of $3.83 million during the quarter, compared to analysts’ expectations of $4.71 million. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The business’s quarterly revenue was down 58.9% compared to the same quarter last year. During the same quarter last year, the business posted ($1.64) EPS. sell-side analysts expect that Portola Pharmaceuticals will post -4.95 EPS for the current year.

Several equities analysts have weighed in on PTLA shares. Oppenheimer reaffirmed a “buy” rating and issued a $80.00 target price on shares of Portola Pharmaceuticals in a research report on Wednesday, September 6th. BidaskClub downgraded Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 7th. Credit Suisse Group raised Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 target price for the company in a research report on Wednesday, August 23rd. Morgan Stanley reaffirmed an “overweight” rating and issued a $81.00 target price (up from $75.00) on shares of Portola Pharmaceuticals in a research report on Friday, October 6th. Finally, Goldman Sachs Group started coverage on Portola Pharmaceuticals in a research report on Friday, December 1st. They issued a “buy” rating and a $75.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $71.15.

WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Insider Buying and Selling by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with's FREE daily email newsletter.